Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account
We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading
Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

Previously untreated Stage III/IV cHL ∨Select
Lymphoma
Type
Previously untreated Stage III/IV cHLPediatric previously untreated high-risk cHLcHL post-auto-HSCT consolidationRelapsed cHLR/R LBCL after ≥2 prior lines of systemic therapyPreviously untreated sALCL or other CD30-expressing PTCLRelapsed pcALCL or CD30-expressing MFRelapsed sALCLLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EfficacySafetyDosageVideo LibraryMOA & Resources ∨MOA &
Resources
Patient ManagementMOA and CD30 TestingResourcesPatient Assistance
Prescribing InformationPatient InformationIndicationsLoadingPatient Site
EfficacyPrimary Endpoint: mPFSECHELON-1 primary endpoint: Modified PFS per IRF at 2 years1,2
  • HR: 0.77 (95% CI: 0.60, 0.98); P = 0.035; median follow-up: 24.6 months
  • 23% reduction in event risk*
  • Number of mPFS events reported were 117 out of 664 patients (17.6%) in the A+AVD group and 146 out of 670 patients (21.8%) in the ABVD group. The reasons leading to mPFS events were as follows1:
    • Disease progression (90 vs 102)
    • Death from any cause (18 vs 22)
    • Subsequent anticancer therapy when complete response was not achieved at completion of frontline therapy (9 vs 22)
An event was defined as progression, death from any cause, or receipt of additional anticancer therapy for patients not in complete remission after first-line therapy.1Overall SurvivalIn a curative intent setting of frontline Stage III/IV cHL, A+AVD demonstrated a statistically significant overall survival benefit vs ABVD1,3,4
  • At 103 events, a benefit was considered statistically significant at P <0.03655
  • Median follow-up: 6.1 years1
  • Median overall survival was not reached in either arm1
  • At 2 years (the time of the modified PFS analysis), an interim overall survival analysis did not demonstrate a significant difference1
Go to OS data in adolescents and young adultsLoading
In a curative intent setting, A+AVD is the first and only regimen in 35 years to demonstrate an overall survival benefit vs ABVD alone in frontline Stage III/IV cHL1,3-5
Example Text
The First Treatment Choice Matters: Patient Case of a Young Adult

“For the first time in 35 years, one treatment demonstrated a survival advantage against a historical standard of care.”
—Dr Andrew Ip, hematologist-oncologist

Dr Andrew Ip is presenting this program on behalf of Pfizer and is contracted with Pfizer for this service.

Play Video Loading

“For the first time in 35 years, one treatment demonstrated a survival advantage against a historical standard of care.”
—Dr Andrew Ip, hematologist-oncologist

Dr Andrew Ip is presenting this program on behalf of Pfizer and is contracted with Pfizer for this service.

Play Video Loading
Additional DataPFS per INV after median follow-up of 6 years (ITT population)5PFS per INV at 6 years was a post hoc exploratory analysis. This non-alpha-controlled analysis cannot be used to determine differences between treatment arms and offers supportive, but not conclusive, clinical information only.
  • PFS per INV was defined as time from randomization to the first occurrence of disease progression or death5
  • Median follow-up: 72.6 months5
  • Median PFS was not reached in either arm5
Go to PFS data in adolescents and young adultsLoadingFewer A+AVD patients received salvage chemotherapy and transplant2This non-prespecified, post hoc exploratory analysis is descriptive in nature and offers supportive, but not conclusive, clinical information only. This analysis was not powered to determine differences between treatment arms.At least 1 subsequent anticancer therapy was reported for 265 patients, 121 of 664 with A+AVD and 144 of 670 with ABVD. Recipients of these therapies in the A+AVD group vs ABVD group were as follows: radiation (in 52 patients in each group), chemotherapy (66 vs 99), high dose chemotherapy + transplant (36 vs 54), immunotherapy (10 vs 16) and  chemotherapy + radiation (2 vs 3).2,6Median follow-up time for both treatment arms was 24.6 months.2
AYA Subgroup Analysis
AYA patients exhibited overall survival results consistent with the ITT population with A+AVD vs ABVD1,7This post hoc exploratory analysis of a non-prespecified subgroup is non-alpha-controlled and cannot be used to determine differences between treatment arms. This offers supportive, but not conclusive, clinical information only.
  • Median OS follow-up in the AYA population: 71.7 months¶8
6 year overall survival rates of patients aged ≥45 years5A+AVD: 84.8% of patients (n=213); ABVD: 80.4% of patients (n=247); HR: 0.75 (95% CI: 0.47, 1.18)Based on Kaplan-Meier product limit estimates [n = number of patients].8Hazard ratio (A+AVD/ABVD) and 95% CI are based on unstratified Cox’s proportional hazard regression model.8Median OS follow-up is calculated from the Kaplan-Meier method switching the OS event/censored status, ie, OS event as censored and censored as OS event.8PFS per INV results for AYA subgroup5,7PFS per INV at 6 years was a post hoc exploratory analysis. This analysis of a non-prespecified subgroup is non–alpha-controlled and cannot be used to determine differences between treatment arms. This offers supportive, but not conclusive, clinical information only.
  • Median PFS follow-up in the AYA population: 71.5 months7
Explore ECHELON-1 Trial DesignMulticenter, open-label, superiority trial1,9 Follow-up: every 3 months for 36 months, then every 6 months until study closure

Primary endpoint: modified PFS per IRF#1,9
Key secondary endpoint: OS9
Post-hoc exploratory endpoint**: PFS per INV at 6 years††5

Selected baseline patient characteristics of the ITT population1,9
  • Age: median 36 years (range, 18-83), with 14% ≥60 years
  • Demographics: 58% male and 84% white
  • Stage: 36% Stage III and 64% Stage IV; 62% with extranodal involvement at diagnosis
  • All IPS scores were included: 21% had IPS 0-1, 53% had IPS 2-3, and 26% had IPS 4-7
Patients in each treatment arm by age group‡‡1,5,9 A modified PFS event was defined as progression, death from any cause, or receipt of additional anticancer therapy for patients not in complete remission after first-line therapy.Assessed periodically, though the analysis at 6 years was not prespecified.A PFS event was defined as progression or death from any cause.Percentages do not add up to 100% due to rounding.A+AVD = ADCETRIS + doxorubicin, vinblastine, dacarbazine; ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; cHL = classical Hodgkin lymphoma; ECOG = Eastern Cooperative Oncology Group; INV = investigator; IPS = international prognostic score; IRF = independent review facility; IV = intravenous; OS = overall survival; PFS = progression-free survival.

A+AVEPC: Approved for pediatric patients 2 years and older
Explore Pediatric Efficacy Loading
< Back Stage III/IV cHL Home Loading
Up next >
Safety Loading
 A+AVD = ADCETRIS + doxorubicin, vinblastine, dacarbazine; ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; AVD = doxorubicin, vinblastine, dacarbazine; AYA = adults and young adolescents; cHL = classical Hodgkin lymphoma; CI = confidence interval; HR = hazard ratio; HSCT = hematopoietic stem cell transplantation; INV = investigator; IRF = Independent review facility; ITT = intent-to-treat; mPFS = modified progression-free survival; OS = overall survival; PFS = progression-free survival.References:ADCETRIS Prescribing Information. Bothell, WA: Seagen Inc.Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378:331-344.Choi Y, Diefenbach CS. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma. Expert Rev Hematol. 2019;12:801-808Ansell SM. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022;97:1478-1488.Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in Stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2022;387:310-320.Data on file. Pfizer Inc.Crosswell HE, LaCasce AS, Bartlett NL. et al. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1. Haematologica. 2024;109(3):982-987.Crosswell HE, LaCasce AS, Bartlett NL, et al. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1. Haematologica. 2023;10.3324. doi:10.3324/haematol.2023.283303Connors JM, Jurczak W, Straus DJ, et al. Protocol for: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378:331-344.
Available on this page:

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-A1T-USA-1084
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
Indications

ADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL

  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.

Previously untreated high risk cHL

  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

cHL post-auto-HSCT consolidation

  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.

Relapsed cHL

  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

Previously untreated sALCL or other CD30-expressing PTCL

  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Relapsed sALCL

  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.

Relapsed pcALCL or CD30-expressing MF

  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.

Relapsed and Refractory Large B-Cell Lymphoma (LBCL)

  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.

Important Safety Information

BOXED WARNING

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.

CONTRAINDICATION

Contraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).

WARNINGS AND PRECAUTIONS
Peripheral neuropathy (PN):
ADCETRIS causes PN that is predominantly sensory. Cases of motor PN have also been reported. ADCETRIS-induced PN is cumulative. Monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. Patients experiencing new or worsening PN may require a delay, change in dose, or discontinuation of ADCETRIS.

Anaphylaxis and infusion reactions: Infusion-related reactions (IRR), including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an IRR occurs, interrupt the infusion and institute appropriate medical management. If anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. Premedicate patients with a prior IRR before subsequent infusions. Premedication may include acetaminophen, an antihistamine, and a corticosteroid.

Hematologic toxicities: Fatal and serious cases of febrile neutropenia have been reported with ADCETRIS. Prolonged (≥1  week) severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS.

Administer G-CSF primary prophylaxis beginning with Cycle 1 for adult  patients who receive ADCETRIS in combination with chemotherapy for previously untreated Stage III/IV cHL or previously untreated PTCL or relapsed or refractory LBCL and pediatric patients who receive ADCETRIS in combination with chemotherapy for previously untreated high risk cHL.

Monitor complete blood counts prior to each ADCETRIS dose. Monitor more frequently for patients with Grade 3 or 4 neutropenia. Monitor patients for fever. If Grade 3 or 4 neutropenia develops, consider dose delays,  reductions, discontinuation, or G-CSF prophylaxis with subsequent doses.

Serious infections and opportunistic infections: Infections such as pneumonia, bacteremia, and sepsis or septic shock (including  fatal outcomes) have been reported in ADCETRIS-treated patients. Closely monitor patients during treatment for infections.

Tumor lysis syndrome: Patients with rapidly proliferating tumor and high tumor burden may be at increased risk. Monitor closely and take appropriate measures.

Increased toxicity in the presence of severe renal impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment. Avoid use in patients with severe renal impairment.

Increased toxicity in the presence of moderate or severe hepatic impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment. Avoid use in patients with moderate or severe hepatic impairment.

Hepatotoxicity: Fatal and serious cases have occurred in ADCETRIS-treated patients. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first ADCETRIS dose or rechallenge. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Monitor liver enzymes and bilirubin. Patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of ADCETRIS.

PML: Fatal cases of JC virus infection resulting in PML have been reported in ADCETRIS-treated patients. First onset of symptoms occurred at various times from initiation of ADCETRIS, with some cases occurring within 3 months of initial exposure. In addition to ADCETRIS therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. Consider PML diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. Hold ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is confirmed.

Pulmonary toxicity: Fatal and serious events of noninfectious pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported. Monitor patients for signs and symptoms, including cough and  dyspnea. In the event of new or worsening pulmonary symptoms, hold ADCETRIS dosing during evaluation and until symptomatic improvement.

Serious dermatologic reactions: Fatal and serious cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. If SJS or TEN occurs, discontinue ADCETRIS and administer appropriate medical therapy.

Gastrointestinal (GI) complications: Fatal and serious cases of acute pancreatitis have been reported. Other fatal and serious GI complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with preexisting GI involvement may increase the risk of perforation. In the event of new or worsening GI symptoms, including severe abdominal pain, perform a prompt diagnostic evaluation and treat appropriately.

Hyperglycemia: Serious cases, such as new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, and ketoacidosis (including fatal outcomes) have been reported with ADCETRIS. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Monitor serum glucose and if hyperglycemia develops, administer anti-hyperglycemic medications as clinically indicated.

Embryo-fetal toxicity: Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS. Advise male patients with female partners of reproductive potential to use effective contraception during ADCETRIS  treatment and for 4 months after the last dose of ADCETRIS.

ADVERSE REACTIONS
The most common adverse reactions (≥20%) in adult patients are  peripheral neuropathy, nausea, fatigue, musculoskeletal pain, constipation, diarrhea, vomiting, pyrexia, upper respiratory tract infection, mucositis, abdominal pain, and rash. The most common laboratory abnormalities (≥20%) in adult patients are decreased  neutrophils, increased creatinine, decreased hemoglobin, decreased lymphocytes, increased glucose, increased ALT, and increased AST. 

The most common Grade ≥3 adverse reactions (≥5%) in combination with AVEPC in pediatric patients were neutropenia, anemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection.

DRUG INTERACTIONS
Concomitant use of strong CYP3A4 inhibitors has the potential to affect  the exposure to monomethyl auristatin E (MMAE). Closely monitor adverse reactions.

USE IN SPECIAL POPULATIONS
Lactation: Breastfeeding is not recommended during ADCETRIS treatment.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.IndicationsADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL
  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
Previously untreated high risk cHL
  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
cHL post-auto-HSCT consolidation
  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
Relapsed cHL
  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
Previously untreated sALCL or other CD30-expressing PTCL
  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
Relapsed sALCL
  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.
Relapsed pcALCL or CD30-expressing MF
  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
Relapsed and Refractory Large B-Cell Lymphoma (LBCL)
  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.